Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/ activated factor XI apple 2 domain

Authors
Category Primary study
JournalEur. Heart J.
Year 2024
This article has no abstract
Epistemonikos ID: 6851d8569cedf87ee3e472604fa5a97552f91035
First added on: Jan 24, 2025